Shire Sees Future For Premature Baby Drug Despite PhII Disappointment
Shire's product candidate for a rare eye disease in premature infants has failed in a Phase II study, but secondary endpoint data suggest SHP607 might still have a future.
Shire's product candidate for a rare eye disease in premature infants has failed in a Phase II study, but secondary endpoint data suggest SHP607 might still have a future.